-+ 0.00%
-+ 0.00%
-+ 0.00%

Rezolute FY26 net loss widens 4.26% to $77.59 million; FY26 G&A expenses climb 58.79% to $29.17 million

PUBT·09/24/2026 20:08:13
Rezolute FY26 net loss widens 4.26% to $77.59 million; FY26 G&A expenses climb 58.79% to $29.17 million
  • Rezolute posted a fiscal 2026 net loss of USD 77.59 million, widening from USD 74.41 million a year earlier.
  • R&D expense fell 12.56% to USD 53.8 million, and the company attributed the drop mainly to lower ersodetug manufacturing costs.
  • G&A expense climbed 58.8% to USD 29.17 million, which it linked to higher stock-based compensation and pre-commercial professional fees.
  • Cash, cash equivalents and marketable securities totaled USD 107.8 million at June 30, 2026, down from USD 167.9 million.
  • Phase 3 upLIFT tumor HI study enrollment continues, with topline results expected before end-2026; sunRIZE congenital HI data remain under FDA review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241605PRIMZONEFULLFEED9833653) on September 24, 2026, and is solely responsible for the information contained therein.